VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Monday, March 31st.

VolitionRx Stock Performance

Shares of VNRX opened at $0.53 on Friday. VolitionRx has a fifty-two week low of $0.43 and a fifty-two week high of $1.02. The company has a market capitalization of $51.39 million, a PE ratio of -1.48 and a beta of 1.15. The stock has a fifty day moving average of $0.58 and a two-hundred day moving average of $0.63.

Insider Activity

In other VolitionRx news, CEO Cameron John Reynolds bought 181,818 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, with a total value of $99,999.90. Following the transaction, the chief executive officer now owns 2,299,222 shares in the company, valued at $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Several institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the 4th quarter valued at $29,000. Millennium Management LLC acquired a new stake in shares of VolitionRx in the fourth quarter valued at about $36,000. Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after buying an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. boosted its holdings in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the period. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.